Famotidine, a new H2-receptor antagonist-Reference-Cited by-同舟云学术

Famotidine, a new H2-receptor antagonist

Published:1985-04 Issue:4 Volume:30 Page:308-312
ISSN:0163-2116
Container-title:Digestive Diseases and Sciences
language:en
Short-container-title:Digest Dis Sci

Author:

Smith J. Lacey,Gamal Mohamed A.,Chremos A. N.,Graham David Y.

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,Physiology

Link

http://link.springer.com/content/pdf/10.1007/BF01403838.pdf

Reference14 articles.

1. Takeda M, Takagi T, Yashima Y, Maeno H: Effect of a new potent H2-blocker, 3-[[[[2-[(diaminomethylene) amino]-4-thiazolyl]methyl]thio]thio]-N2-sulfamyl propionamidine (YM-11170), on gastric secretion, ulcer formation and weight of male accessory sex organs in rats. Arzneim Forsch/Drug Res 32:734, 1982

2. Zar JH: Biostatistical Analysis. Englewood Cliffs, New Jersey, Prentice-Hall, 1974

3. Hassan MA, Hobsley M: Positioning of subject and of nasogastric tube during a gastric secretion study. Br Med J 1:458?460, 1970

4. Berstad A: A modified hemoglobin substrate method for the estimation of pepsin in gastric juice. Scand J Gastroenterol 5:343?348, 1970

5. Samloff IM, Dadulfalza V: Biochemical studies of human group I and group II pepsins. Gastroenterology 70:963, 1976 (abstract)

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pentabromobenzyl-RP versus triazole-HILIC columns for separation of the polar basic analytes famotidine and famotidone: LC method development combined with in silico tools to follow the potential consequences of famotidine gastric instability;Journal of Pharmaceutical and Biomedical Analysis;2020-07

2. Impact of Acid-Reducing Agents on Gastrointestinal Physiology and Design of Biorelevant Dissolution Tests to Reflect These Changes;Journal of Pharmaceutical Sciences;2019-11

3. One-year safety of ibuprofen/famotidine fixed combination versus ibuprofen alone: pooled analyses of two 24-week randomized, double-blind trials and a follow-on extension;Current Medical Research and Opinion;2015-01-12

4. DUEXIS® (ibuprofen 800 mg, famotidine 26.6 mg): a new approach to gastroprotection for patients with chronic pain and inflammation who require treatment with a nonsteroidal anti-inflammatory drug;Therapeutic Advances in Musculoskeletal Disease;2012-04-25

5. Single night-time doses of 40 mg famotidine or 800 mg cimetidine in the treatment of duodenal ulcer;Alimentary Pharmacology & Therapeutics;2007-03-31